FR25C1016I2 - Utilisation de l'inhibiteur de la télomérase imetelstat pour le traitement du syndrome myélodysplasique - Google Patents

Utilisation de l'inhibiteur de la télomérase imetelstat pour le traitement du syndrome myélodysplasique

Info

Publication number
FR25C1016I2
FR25C1016I2 FR25C1016C FR25C1016C FR25C1016I2 FR 25C1016 I2 FR25C1016 I2 FR 25C1016I2 FR 25C1016 C FR25C1016 C FR 25C1016C FR 25C1016 C FR25C1016 C FR 25C1016C FR 25C1016 I2 FR25C1016 I2 FR 25C1016I2
Authority
FR
France
Prior art keywords
treatment
myelodysplastic syndrome
telomerase inhibitor
imetelstat
inhibitor imetelstat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR25C1016C
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed filed Critical
Publication of FR25C1016I1 publication Critical patent/FR25C1016I1/fr
Application granted granted Critical
Publication of FR25C1016I2 publication Critical patent/FR25C1016I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
FR25C1016C 2012-12-07 2025-05-07 Utilisation de l'inhibiteur de la télomérase imetelstat pour le traitement du syndrome myélodysplasique Active FR25C1016I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05
PCT/US2013/070437 WO2014088785A1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
EP13861008.4A EP2928477B1 (fr) 2012-12-07 2013-11-15 Utilisation de l'inhibiteur de télomérase imetelstat pour le traitement de la myelofibrose

Publications (2)

Publication Number Publication Date
FR25C1016I1 FR25C1016I1 (fr) 2025-06-20
FR25C1016I2 true FR25C1016I2 (fr) 2026-04-17

Family

ID=50883867

Family Applications (1)

Application Number Title Priority Date Filing Date
FR25C1016C Active FR25C1016I2 (fr) 2012-12-07 2025-05-07 Utilisation de l'inhibiteur de la télomérase imetelstat pour le traitement du syndrome myélodysplasique

Country Status (37)

Country Link
EP (3) EP3456333B8 (fr)
JP (6) JP6433911B2 (fr)
KR (4) KR20230028590A (fr)
CN (2) CN104936602B (fr)
AP (1) AP2015008504A0 (fr)
AU (4) AU2013356533B2 (fr)
BR (1) BR112015013260A2 (fr)
CA (2) CA3188494A1 (fr)
CL (2) CL2015001530A1 (fr)
CY (3) CY1122169T1 (fr)
DK (3) DK2928477T3 (fr)
EA (1) EA032973B1 (fr)
ES (3) ES2982897T3 (fr)
FI (2) FI3646876T3 (fr)
FR (1) FR25C1016I2 (fr)
HK (1) HK1210940A1 (fr)
HR (3) HRP20191784T1 (fr)
HU (4) HUE049858T2 (fr)
IL (3) IL280144B2 (fr)
LT (4) LT3646876T (fr)
MA (2) MA38193B1 (fr)
ME (1) ME03538B (fr)
MX (3) MX372753B (fr)
MY (2) MY180634A (fr)
NL (1) NL301326I2 (fr)
NZ (1) NZ708920A (fr)
PH (2) PH12019501008A1 (fr)
PL (3) PL3646876T3 (fr)
PT (3) PT2928477T (fr)
RS (2) RS60401B1 (fr)
SG (3) SG10202103341SA (fr)
SI (3) SI3456333T1 (fr)
SM (2) SMT201900567T1 (fr)
TN (1) TN2015000249A1 (fr)
UA (3) UA128370C2 (fr)
WO (1) WO2014088785A1 (fr)
ZA (3) ZA201504124B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100558739C (zh) 2004-07-02 2009-11-11 杰龙公司 合成被保护的3’-氨基核苷单体
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
RS58659B1 (sr) * 2013-11-06 2019-05-31 Mayo Found Medical Education & Res Postupci i materijali za tretiranje hematoloških maligniteta
CN113564168B (zh) * 2015-04-23 2024-10-25 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法
EP3318276A1 (fr) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
WO2019023667A1 (fr) * 2017-07-28 2019-01-31 Janssen Biotech, Inc. Procédés de traitement du syndrome myélodysplasique
IL308399B2 (en) 2018-04-30 2025-08-01 Kartos Therapeutics Inc Methods of treating cancer
EP3801476A4 (fr) * 2018-05-25 2022-07-06 Kartos Therapeutics, Inc. Méthodes de traitement des néoplasmes myéloprolifératifs
CN112770783B (zh) * 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
EP3887537A4 (fr) 2018-11-29 2023-04-12 Geron Corporation Procédés de traitement du syndrome myélodysplasique
TW202133854A (zh) 2019-11-04 2021-09-16 美商傑龍公司 詹納斯(janus)激酶抑制劑及端粒酶抑制劑於治療骨髓增生性腫瘤之用途
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
CN115776909A (zh) * 2020-07-17 2023-03-10 美国杰龙生物医药公司 皮下端粒酶抑制剂组合物及其使用方法
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法
WO2024259369A1 (fr) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions ciblant des cellules géantes dans des troubles sanguins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
WO2004070008A2 (fr) * 2003-01-31 2004-08-19 Au Jessie L-S Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
SI3342425T1 (sl) 2003-09-09 2020-04-30 Geron Corporation Modificirani oligonukleotidi za inhibicijo telomeraze
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
CN100558739C (zh) 2004-07-02 2009-11-11 杰龙公司 合成被保护的3’-氨基核苷单体
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (fr) * 2005-04-15 2006-10-26 Geron Corporation Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
WO2006113470A2 (fr) 2005-04-15 2006-10-26 Geron Corporation Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
PT2101789E (pt) * 2006-10-30 2015-03-24 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
UA128370C2 (uk) 2024-06-26
RS59363B1 (sr) 2019-11-29
FI3646876T3 (fi) 2024-05-14
CN111617252A (zh) 2020-09-04
HK1212226A1 (en) 2016-06-10
HK1210940A1 (zh) 2016-05-13
CN104936602B (zh) 2020-07-17
WO2014088785A8 (fr) 2015-07-16
AU2013356533A1 (en) 2014-06-12
JP2020041001A (ja) 2020-03-19
AU2013356533B2 (en) 2018-09-27
CL2017002156A1 (es) 2018-05-04
HUS2500019I1 (hu) 2025-05-28
EP2928477A1 (fr) 2015-10-14
MA38193A1 (fr) 2017-12-29
CN104936602A (zh) 2015-09-23
ES2789176T3 (es) 2020-10-26
KR20150091130A (ko) 2015-08-07
JP7288098B2 (ja) 2023-06-06
AU2020267142B2 (en) 2024-05-16
AU2020267142C1 (en) 2024-08-08
IL239266B (en) 2019-11-28
CL2015001530A1 (es) 2016-03-28
IL280144B1 (en) 2025-01-01
EP2928477A4 (fr) 2016-09-21
PH12015501282B1 (en) 2015-08-24
SI3456333T1 (sl) 2020-10-30
IL317233A (en) 2025-01-01
MA45504A1 (fr) 2020-05-29
LTPA2025517I1 (fr) 2025-05-26
PT2928477T (pt) 2019-10-25
CA2892907C (fr) 2023-03-21
DK3646876T3 (da) 2024-05-06
DK3456333T3 (da) 2020-05-18
AU2018282364A1 (en) 2019-05-23
EP3456333B8 (fr) 2020-05-13
JP6433911B2 (ja) 2018-12-05
JP2016504307A (ja) 2016-02-12
MA45504B1 (fr) 2021-10-29
PL2928477T3 (pl) 2020-03-31
MX2022015437A (es) 2023-01-11
PL3646876T3 (pl) 2024-07-22
EP2928477B1 (fr) 2019-07-24
KR20250114449A (ko) 2025-07-29
CA3188494A1 (fr) 2014-06-12
ME03538B (fr) 2020-07-20
ZA202212327B (en) 2025-03-26
HRP20191784T1 (hr) 2019-12-27
IL280144A (en) 2021-03-01
MX2020003276A (es) 2020-07-20
JP2022050537A (ja) 2022-03-30
JP2025109842A (ja) 2025-07-25
MY200076A (en) 2023-12-06
HUE049858T2 (hu) 2020-11-30
KR20230028590A (ko) 2023-02-28
JP2022179684A (ja) 2022-12-02
ZA201504124B (en) 2017-05-31
PH12015501282A1 (en) 2015-08-24
SI3646876T1 (sl) 2024-07-31
SG11201504383TA (en) 2015-07-30
RS60401B1 (sr) 2020-07-31
PL3456333T3 (pl) 2020-09-21
FR25C1016I1 (fr) 2025-06-20
NL301326I2 (nl) 2025-07-31
PT3646876T (pt) 2024-05-15
HRP20240624T1 (hr) 2024-08-02
HUE066402T2 (hu) 2024-07-28
KR20210107906A (ko) 2021-09-01
ES2982897T3 (es) 2024-10-18
AU2024203138A1 (en) 2024-07-25
MX2015007169A (es) 2016-03-31
SMT201900567T1 (it) 2019-11-13
KR102662590B1 (ko) 2024-05-03
SI2928477T1 (sl) 2019-11-29
EP3456333B1 (fr) 2020-04-01
LT2928477T (lt) 2019-10-10
CA2892907A1 (fr) 2014-06-12
ZA202108991B (en) 2023-05-31
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
LT3646876T (lt) 2024-05-10
CY1122169T1 (el) 2020-11-25
EA032973B1 (ru) 2019-08-30
TN2015000249A1 (en) 2016-10-03
SMT202000328T1 (it) 2020-07-08
SG10202103341SA (en) 2021-05-28
EA201590878A1 (ru) 2016-04-29
LT3456333T (lt) 2020-06-25
UA117116C2 (uk) 2018-06-25
PT3456333T (pt) 2020-06-01
MA38193B1 (fr) 2018-12-31
PH12019501008A1 (en) 2022-11-14
NZ748134A (en) 2020-10-30
JP2018035196A (ja) 2018-03-08
FIC20250019I1 (fi) 2025-05-07
CY2025015I2 (el) 2026-02-25
ES2744790T3 (es) 2020-02-26
EP3646876B1 (fr) 2024-02-14
CY1123206T1 (el) 2021-10-29
AP2015008504A0 (en) 2015-06-30
KR102294819B1 (ko) 2021-09-01
CY2025015I1 (el) 2026-02-25
IL239266A0 (en) 2015-07-30
DK2928477T3 (da) 2019-10-07
EP3646876A1 (fr) 2020-05-06
MY180634A (en) 2020-12-03
JP6998191B2 (ja) 2022-02-04
WO2014088785A1 (fr) 2014-06-12
UA126015C2 (uk) 2022-08-03
EP3456333A1 (fr) 2019-03-20
MX372753B (es) 2020-06-26
BR112015013260A2 (pt) 2018-02-06
SG10201802926XA (en) 2018-05-30
IL280144B2 (en) 2025-05-01
NZ708920A (en) 2020-08-28
AU2020267142A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
FR25C1016I1 (fr) Utilisation de l'inhibiteur de la télomérase imetelstat pour le traitement du syndrome myélodysplasique
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
EP2911669A4 (fr) Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP2882444A4 (fr) Silicate de zirconium microporeux pour le traitement de l'hyperkaliémie
EP2875824A4 (fr) Composition pour la prévention ou le traitement de la cachexie
EP2755676A4 (fr) Composition et pansement pour le traitement de blessures
EP2914274A4 (fr) Probiotique modifié génétiquement pour le traitement de la phénylcétonurie
EP2568999A4 (fr) Acth pour le traitement de la sclérose latérale amyotrophique
EP2797424A4 (fr) Rétention de dha pendant le traitement du canola
FR3013184B1 (fr) Utilisation d'hydroxyapatite pour le traitement de l'esca
EP2544692A4 (fr) Utilisation de la tigécycline pour le traitement du cancer
EP2837381A4 (fr) Utilisation d'agents modificateurs de l'environnement péritumoral pour le traitement du cancer
FR20C1044I2 (fr) Triazines pour le traitement des infections protozoïques
EP2905027A4 (fr) Utilisation de mycobacterium brumae pour le traitement du cancer de la vessie
EP2900229A4 (fr) Inhibiteurs de télomérase pour l'utilisation en thérapie
EP2950798A4 (fr) Agonistes de ppar pour le traitement de la sclérose en plaques
EP2702992A4 (fr) Utilisation de mélatonine pour le traitement et/ou la prévention de la mucosite
EP2968478A4 (fr) Compositions et procédés pour le traitement de la carboxyhémoglobinémie
EP2536436A4 (fr) Antimir-451 pour le traitement de polycythémies
EP2704711A4 (fr) Utilisation de fk506 pour traitement d'hypertension artérielle pulmonaire
EP2967824A4 (fr) Dispositif vaso-occlusif enduit pour le traitement d'anévrysmes
EP2886122A4 (fr) Agent pour le traitement du cancer
EP2986120A4 (fr) Inhibiteurs de méthyltransférase pour le traitement du cancer
FR3002146B1 (fr) Utilisation d'hemoglobine d'annelides pour traiter les cancers